In a patient taking quetiapine 25 mg at bedtime and trazodone 50 mg at night who continues to have nocturnal wandering and sundowning, what management strategies are recommended?

Optimize Current Medications and Consider Safer Alternatives

The patient's current regimen of quetiapine 25 mg and trazodone 50 mg is inadequate for controlling nocturnal wandering and sundowning, and both doses should be optimized before adding new agents. However, recent evidence raises significant safety concerns about low-dose quetiapine in older adults that warrant serious consideration of alternative strategies.

Critical Safety Concern with Current Quetiapine Use

Low-dose quetiapine for sleep in older adults is associated with substantially increased risks of mortality (HR 3.1), dementia (HR 8.1), and falls (HR 2.8) compared to trazodone 1. The 2020 VA/DoD guidelines explicitly advise against using antipsychotics like quetiapine for insomnia, noting that evidence is sparse and harms are well-documented, including increased mortality in elderly patients with dementia 2. The FDA drug label warns of increased death risk in elderly patients with dementia-related psychosis 3.

Immediate Management Strategy

Step 1: Address Underlying Contributors

Before medication adjustments, systematically evaluate and treat:

• Pain management: Uncontrolled pain (arthritis, other sources) frequently triggers agitation and wandering 4
• Delirium triggers: Urinary retention, constipation, infections (UTI), hypoxia 5
• Medication review: Corticosteroids, opioids, anticonvulsants can worsen sleep-wake disturbances 6
• Environmental factors: Ensure adequate lighting in evening hours, simplify environment, remove safety hazards 4

Step 2: Optimize Trazodone First

Increase trazodone from 50 mg to 100-200 mg at bedtime 7, 6. Trazodone at 25-100 mg is recommended for insomnia in palliative care settings, with doses up to 200-400 mg daily in divided doses for severe agitation 7. Recent evidence shows trazodone improves sleep efficiency and total nocturnal sleep time in dementia patients 8, 9, and demonstrates better safety than low-dose quetiapine in older adults 1, 10.

Common pitfall: Using inadequate trazodone doses. The current 50 mg dose is at the lower end of the therapeutic range for behavioral disturbances.

Step 3: Consider Discontinuing or Replacing Quetiapine

Given the safety data, strongly consider tapering quetiapine and relying on optimized trazodone alone 1. If an atypical antipsychotic remains necessary for severe agitation:

• Olanzapine 2.5-5 mg at bedtime is an alternative option 6, though it carries similar risks in elderly patients with dementia
• The 2002 Alzheimer's guidelines note quetiapine starting dose should be 12.5 mg twice daily (not just 25 mg at bedtime), with maximum 200 mg twice daily, and warn about transient orthostasis 7

Step 4: Non-Pharmacological Interventions (Essential)

These are not optional add-ons but core treatment components:

• Structured daily routine: Establish consistent sleep-wake times, meaningful daytime activities to reduce nocturnal restlessness 4
• Sleep hygiene: Avoid daytime napping, ensure physical activity earlier in day, limit evening fluids 11, 6
• Communication strategies: Use calm tones, simple single-step commands, avoid confrontational interactions during evening hours 4
• Environmental modifications: Night lights to reduce disorientation, secure wandering paths, remove trip hazards 4
• Caregiver education: Explain that behaviors are not intentional, teach de-escalation techniques 4

If Symptoms Persist After Optimization

Only after maximizing trazodone (100-200 mg) and implementing non-pharmacological strategies:

• Consider adding low-dose lorazepam 0.5-1 mg at bedtime for breakthrough agitation 6, though benzodiazepines carry fall and cognitive impairment risks in elderly 2
• Mirtazapine 7.5-30 mg at bedtime is another alternative with sedating properties 6
• Melatonin may help with circadian rhythm disturbances and "sundowning" 12

Critical Monitoring

• Falls risk: Both current medications increase fall risk; assess home safety, consider physical therapy 3
• Orthostatic hypotension: Check blood pressure sitting and standing, especially after dose changes 7, 3
• Cognitive function: Monitor for worsening confusion or new-onset delirium 1
• Paradoxical effects: Quetiapine can rarely cause sleepwalking and complex motor behaviors 13, 14

The evidence strongly suggests that continuing low-dose quetiapine for insomnia in this older adult carries unacceptable risks 1. Prioritize optimizing trazodone dosing, implementing robust non-pharmacological interventions, and seriously considering quetiapine discontinuation to minimize mortality, dementia progression, and fall risks while addressing the underlying behavioral disturbances.